Can a cancer drug slow down a rare leukemia?
NCT ID NCT03722407
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests the drug ruxolitinib (Jakafi) in 29 people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if the drug can improve blood counts, shrink the cancer, or delay its turning into a more aggressive leukemia. Researchers are also checking how safe the drug is and how long any benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib (also known as Jakafi)
What this could lead to
If successful, this could offer a new treatment option to control CMML and delay its progression to acute leukemia.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
Weill Medical College of Cornell University
New York, New York, 10021, United States